Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

BPMC

Blueprint Medicines Corp

Apr 30 • 04:00PM ET

91.34

Dollar change -1.76
Percentage change -1.89	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IWM VXF VBK IWO IBB SCHA VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-8.37	Insider Own	2.33%	Shs Outstand	61.15M	Perf Week	-1.03%
Market Cap	5.59B	Forward P/E	-	EPS next Y	-2.82	Insider Trans	-11.99%	Shs Float	59.80M	Perf Month	-5.27%
Income	-506.98M	PEG	-	EPS next Q	-1.67	Inst Own	106.21%	Short Float	7.10%	Perf Quarter	9.36%
Sales	249.38M	P/S	22.43	EPS this Y	32.99%	Inst Trans	-2.82%	Short Ratio	5.31	Perf Half Y	66.65%
Book/sh	2.14	P/B	42.76	EPS next Y	49.72%	ROA	-42.26%	Short Interest	4.25M	Perf Year	78.92%
Cash/sh	11.61	P/C	7.87	EPS next 5Y	-	ROE	-157.13%	52W Range	43.89 - 101.00	Perf YTD	-0.98%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-9.19%	ROI	-61.58%	52W High	-9.56%	Beta	0.65
Dividend TTM	-	Quick Ratio	3.66	Sales past 5Y	220.20%	Gross Margin	87.46%	52W Low	108.11%	ATR (14)	4.15
Dividend Ex-Date	-	Current Ratio	3.76	EPS Y/Y TTM	10.38%	Oper. Margin	-194.99%	RSI (14)	52.04	Volatility	3.82% 4.44%
Employees	655	Debt/Eq	5.93	Sales Y/Y TTM	22.22%	Profit Margin	-203.30%	Recom	1.88	Target Price	98.00
Option/Short	Yes / Yes	LT Debt/Eq	5.30	EPS Q/Q	31.25%	Payout	-	Rel Volume	0.65	Prev Close	93.10
Sales Surprise	7.21%	EPS Surprise	10.77%	Sales Q/Q	85.55%	Earnings	May 02 BMO	Avg Volume	799.78K	Price	91.34
SMA20	1.08%	SMA50	0.65%	SMA200	29.52%	Trades		Volume	517,046	Change	-1.89%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-27-23	Upgrade	Oppenheimer	Perform → Outperform	$85
Aug-21-23	Reiterated	Needham	Buy	$65 → $66
Jul-31-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$55 → $82
Jun-05-23	Downgrade	SVB Securities	Market Perform → Underperform	$48 → $43
Jan-03-23	Upgrade	Wells Fargo	Underweight → Equal Weight	$41
Dec-14-22	Initiated	Needham	Buy	$60
Nov-02-22	Downgrade	Oppenheimer	Outperform → Perform
Sep-14-22	Initiated	Berenberg	Buy	$90
Jul-08-22	Initiated	Oppenheimer	Outperform	$80
Jun-27-22	Initiated	Wells Fargo	Underweight	$40
Jun-10-22	Downgrade	Citigroup	Neutral → Sell	$68 → $41
Jun-01-22	Upgrade	Jefferies	Hold → Buy	$88 → $78
Mar-01-22	Initiated	Citigroup	Neutral	$71
Feb-17-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$82
Jan-25-22	Upgrade	Stifel	Hold → Buy	$120 → $95
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight	$111
Sep-30-21	Resumed	Stifel	Hold	$105
Jun-04-21	Resumed	Robert W. Baird	Outperform	$119
Mar-31-21	Initiated	Credit Suisse	Neutral	$100
Dec-03-20	Initiated	Stifel	Hold	$110

Show Previous Ratings

Apr-25-24 10:01AM	Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-18-24 08:00AM	Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 (PR Newswire)
Apr-11-24 08:00AM	Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics (PR Newswire)
Apr-04-24 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-28-24 08:13AM	Insiders Are Dumping These 10 Healthcare Stocks (Insider Monkey)
08:50AM	Loading…
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-15-24 07:00PM	Blueprint Medicines Corp's Chief Commercial Officer Sells Company Shares (GuruFocus.com)
Mar-06-24 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
11:53AM	Q4 2023 Rigel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-23-24 08:00AM	Blueprint Medicines Highlights AYVAKIT (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting (PR Newswire)
Feb-16-24 03:30PM	Here's What Key Metrics Tell Us About Blueprint Medicines (BPMC) Q4 Earnings (Zacks)
09:37AM	Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2023 Earnings Call Transcript (Insider Monkey)
05:47AM	Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines (Zacks)
Feb-15-24 10:50PM	Q4 2023 Blueprint Medicines Corp Earnings Call (Thomson Reuters StreetEvents) +14.02%
10:55AM	Blueprint Medicines Surges After Rare-Disease Drug Notches Its Fourth Quarterly Beat (Investor's Business Daily)
08:25AM	Loading…
08:25AM	Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:43AM	Blueprint Medicines Corp Reports Robust AYVAKIT Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
07:26AM	Blueprint Medicines: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Blueprint Medicines Outranks 92% Of All Stocks. But This Could Be Its Undoing. (Investor's Business Daily)
07:00AM	Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results (PR Newswire)
Feb-12-24 09:16AM	Seeking Clues to Blueprint Medicines (BPMC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Feb-08-24 10:00AM	Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-05-24 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Feb-01-24 08:00AM	Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024 (PR Newswire)
Jan-16-24 12:00PM	What Makes Blueprint Medicines (BPMC) a New Buy Stock (Zacks)
11:51AM	Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now (Zacks)
Jan-09-24 01:51PM	Biotech Is Ripe for M&A. These May Be the Next Acquisition Targets. (Barrons.com)
Jan-08-24 08:00AM	Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-05-24 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-18-23 08:00AM	Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
11:05AM	Loading…
Dec-14-23 11:05AM	Insider Sell: Director Jeffrey Albers Sells 5,000 Shares of Blueprint Medicines Corp (BPMC) (GuruFocus.com)
Dec-12-23 08:05AM	Blueprint Medicines' AYVAKYT (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis (PR Newswire)
Dec-10-23 11:59AM	12 Best Genomics Stocks To Buy Now (Insider Monkey)
Dec-09-23 12:30PM	Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting (PR Newswire)
Dec-04-23 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-28-23 08:00AM	Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit (PR Newswire)
Nov-14-23 05:05PM	FMR LLC Adjusts Stake in Blueprint Medicines Corp (GuruFocus.com) +9.97%
Nov-13-23 04:29PM	Oppenheimer Expects the S&P 500s Advance to Continue Into 2024 Heres Why These 2 Stocks Might Be Worth Buying (TipRanks)
Nov-10-23 08:00AM	Blueprint Medicines' AYVAKYT (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis (PR Newswire)
Nov-04-23 03:02AM	Director Jeffrey Albers Sells 10,000 Shares of Blueprint Medicines Corp (GuruFocus.com)
Nov-03-23 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-31-23 09:55AM	How Much Upside is Left in Blueprint Medicines (BPMC)? Wall Street Analysts Think 42.16% (Zacks) +8.32%
09:40AM	Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year? (Zacks)
03:48AM	5 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts (Insider Monkey)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-28-23 01:49PM	Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-27-23 10:01AM	Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls (The Fly)
07:27AM	Blueprint (BPMC) Stock Gains 26% on Q3 Earnings & Sales Beat (Zacks)
Oct-26-23 11:42PM	Q3 2023 Blueprint Medicines Corp Earnings Call (Thomson Reuters StreetEvents) +25.61%
05:47PM	Why Blueprint Medicines Stock Soared Today (Motley Fool)
09:30AM	Compared to Estimates, Blueprint Medicines (BPMC) Q3 Earnings: A Look at Key Metrics (Zacks)
08:52AM	Blueprint Medicines Corp (BPMC) Reports Q3 2023 Earnings (GuruFocus.com)
08:15AM	Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:09AM	Blueprint Medicines: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Blueprint Medicines Reports Third Quarter 2023 Results (PR Newswire)
Oct-25-23 10:15AM	Drug, Biotech Stocks' Q3 Earnings Due on Oct 26: BMY, MRK, BPMC (Zacks)
Oct-23-23 08:30AM	Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board (PR Newswire)
Oct-20-23 10:00AM	AC Immune (ACIU) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-19-23 10:01AM	Earnings Preview: Blueprint Medicines (BPMC) Q3 Earnings Expected to Decline (Zacks) -5.27%
Oct-12-23 08:00AM	Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023 (PR Newswire)
Oct-06-23 03:00AM	Insider Sell: Fouad Namouni Sells 3,769 Shares of Blueprint Medicines Corp (GuruFocus.com)
Oct-05-23 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +6.73%
Sep-29-23 11:01PM	Director Jeffrey Albers Sells 25,000 Shares of Blueprint Medicines Corp (GuruFocus.com)
Sep-08-23 11:30AM	Deciphera Pharmaceuticals, Inc. (DCPH) Down 9.7% Since Last Earnings Report: Can It Rebound? (Zacks) +5.41%
Sep-07-23 11:30AM	Why Is Iovance Biotherapeutics (IOVA) Down 21.2% Since Last Earnings Report? (Zacks)
Sep-05-23 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-01-23 11:31AM	Why Is Blueprint Medicines (BPMC) Down 2% Since Last Earnings Report? (Zacks)
Aug-04-23 04:16PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-02-23 01:00PM	Why Shares of Blueprint Medicines Are Falling Wednesday (Motley Fool) -15.34%
12:42PM	Blueprint (BPMC) Q2 Earnings and Revenues Beat Estimates (Zacks)
09:30AM	Blueprint Medicines (BPMC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:25AM	Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:14AM	Blueprint Medicines: Q2 Earnings Snapshot (AP Finance)
07:00AM	Blueprint Medicines Reports Second Quarter 2023 Results (PR Newswire)
Jul-19-23 08:00AM	Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023 (PR Newswire)
Jul-14-23 11:53AM	3 Biotech Stocks Using AI to Change Healthcare Forever (InvestorPlace)
Jul-05-23 04:30PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-30-23 08:56AM	UPDATE 1-Genentech withdraws use of Gavreto in US for a type of thyroid cancer, says partner Blueprint (Reuters)
06:26AM	Blueprint Medicines says partner Genentech withdraws use of Gavreto for thyroid cancer (Reuters)
Jun-12-23 09:30AM	3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon (InvestorPlace)
Jun-09-23 09:22AM	Blueprint Medicines (NASDAQ:BPMC) investors are sitting on a loss of 24% if they invested five years ago (Simply Wall St.)
Jun-05-23 05:00PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-04-23 08:45AM	This Biotech Could Soon Go Parabolic, But Should You Buy It? (Motley Fool)
Jun-03-23 09:00AM	Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting (PR Newswire)
May-23-23 10:00AM	NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis (PR Newswire)
May-22-23 04:04PM	FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis (PR Newswire)
May-05-23 06:54AM	Blueprint's (BPMC) Q1 Earnings & Sales Top Estimates, View Up (Zacks)
May-04-23 05:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +12.59%
08:25AM	Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:25AM	Blueprint Medicines: Q1 Earnings Snapshot (AP Finance)
07:00AM	Blueprint Medicines Reports First Quarter 2023 Results (PR Newswire)
May-01-23 10:01AM	Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-27-23 10:02AM	Analysts Estimate Blueprint Medicines (BPMC) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-26-23 10:00AM	Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting (PR Newswire)
Apr-20-23 04:01PM	Blueprint Medicines to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023 (PR Newswire)
Apr-19-23 08:07AM	Blueprint Medicines Corporation's (NASDAQ:BPMC) Shares May Have Run Too Fast Too Soon (Simply Wall St.)
Apr-11-23 08:00AM	Blueprint Medicines to Present at Upcoming Investor Conferences (PR Newswire)
Apr-05-23 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-31-23 11:30AM	Horizon Therapeutics (HZNP) Down 0.9% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-29-23 08:31AM	FDA Removes Partial Clinical Hold From Blueprint Medicines' Cancer Study (Benzinga) +5.64%

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Landsittel Michael	CHIEF FINANCIAL OFFICER	Mar 28 '24	Option Exercise	36.05	5,000	180,250	52,286	Apr 01 04:34 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Mar 28 '24	Sale	95.00	5,000	475,000	47,286	Apr 01 04:34 PM
Albers Jeffrey W.	Director	Mar 20 '24	Option Exercise	7.11	25,073	178,287	201,123	Mar 22 05:50 PM
Albers Jeffrey W.	Director	Mar 20 '24	Sale	87.28	25,073	2,188,264	176,050	Mar 22 05:50 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Mar 15 '24	Option Exercise	36.05	5,000	180,250	61,020	Mar 19 05:11 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Mar 15 '24	Option Exercise	15.01	1,600	24,016	18,662	Mar 19 04:48 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Mar 15 '24	Sale	87.78	13,734	1,205,606	47,286	Mar 19 05:11 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Mar 15 '24	Sale	87.76	4,549	399,213	14,913	Mar 19 04:48 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Mar 13 '24	Option Exercise	13.15	1,747	22,975	42,752	Mar 15 04:47 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Mar 13 '24	Sale	90.40	8,023	725,277	34,729	Mar 15 04:47 PM
Haviland Kate	CHIEF EXECUTIVE OFFICER	Mar 07 '24	Sale	90.69	12,464	1,130,360	153,177	Mar 11 06:27 PM
Albers Jeffrey W.	Director	Mar 07 '24	Sale	90.69	11,033	1,000,583	165,017	Mar 26 09:11 PM
Rossi Christina	CHIEF OPERATING OFFICER	Mar 07 '24	Sale	90.69	6,070	550,488	64,306	Mar 11 06:21 PM
McCain Tracey L	EVP AND CHIEF LEGAL OFFICER	Mar 07 '24	Sale	90.69	5,194	471,044	60,498	Mar 11 06:18 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Mar 07 '24	Sale	90.69	5,093	461,884	57,585	Mar 11 06:28 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Mar 07 '24	Sale	90.69	5,003	453,722	56,020	Mar 11 06:23 PM
Namouni Fouad	PRESIDENT, R & D	Mar 07 '24	Sale	90.69	4,377	396,950	72,703	Mar 11 06:20 PM
Hewes L. Becker	CHIEF MEDICAL OFFICER	Mar 07 '24	Sale	90.69	3,097	280,867	46,281	Mar 11 06:29 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Mar 07 '24	Sale	90.69	2,934	266,084	41,005	Mar 11 06:26 PM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Mar 07 '24	Sale	90.69	2,521	228,629	33,853	Mar 11 06:24 PM
Carter Percy H.	CHIEF SCIENTIFIC OFFICER	Mar 07 '24	Sale	90.69	2,286	207,317	48,331	Mar 11 06:19 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Mar 07 '24	Sale	90.69	1,462	132,589	17,862	Mar 11 06:15 PM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Mar 04 '24	Sale	93.65	621	58,157	36,374	Mar 06 10:41 AM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Feb 28 '24	Option Exercise	54.13	5,000	270,650	29,495	Mar 01 03:06 PM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Feb 28 '24	Sale	100.00	5,000	500,000	24,495	Mar 01 03:06 PM
Albers Jeffrey W.	Director	Jan 25 '24	Option Exercise	7.13	25,000	178,150	201,050	Jan 29 06:13 PM
Albers Jeffrey W.	Director	Jan 25 '24	Sale	81.91	25,000	2,047,800	176,050	Jan 29 06:13 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Dec 22 '23	Option Exercise	8.80	714	6,283	15,038	Dec 26 04:24 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Dec 22 '23	Sale	90.00	714	64,260	14,324	Dec 26 04:24 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Dec 15 '23	Option Exercise	1.87	3,654	6,833	16,411	Dec 19 04:05 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Dec 15 '23	Sale	84.35	3,914	330,146	14,324	Dec 19 04:05 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Dec 13 '23	Option Exercise	1.87	261	488	31,439	Feb 14 06:54 PM
Albers Jeffrey W.	Director	Dec 11 '23	Option Exercise	36.05	5,000	180,250	181,050	Dec 13 03:56 PM
Albers Jeffrey W.	Director	Dec 11 '23	Sale	79.07	5,000	395,350	176,050	Dec 13 03:56 PM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Dec 07 '23	Option Exercise	54.13	5,000	270,650	29,495	Dec 11 05:11 PM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Dec 07 '23	Sale	75.00	5,000	375,000	24,495	Dec 11 05:11 PM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Dec 04 '23	Sale	71.43	600	42,858	24,495	Dec 06 08:45 PM
Albers Jeffrey W.	Director	Nov 30 '23	Option Exercise	36.05	5,000	180,250	181,050	Dec 04 04:02 PM
Albers Jeffrey W.	Director	Nov 30 '23	Sale	70.55	5,000	352,750	176,050	Dec 04 04:02 PM
Albers Jeffrey W.	Director	Nov 24 '23	Option Exercise	1.87	15,000	28,050	191,050	Nov 28 04:05 PM
Albers Jeffrey W.	Director	Nov 24 '23	Sale	67.51	15,000	1,012,690	176,050	Nov 28 04:05 PM
Albers Jeffrey W.	Director	Nov 03 '23	Option Exercise	36.05	1,485	53,534	177,535	Nov 03 05:07 PM
Albers Jeffrey W.	Director	Nov 03 '23	Sale	60.13	1,485	89,293	176,050	Nov 03 05:07 PM
Albers Jeffrey W.	Director	Nov 02 '23	Option Exercise	36.05	4,634	167,056	180,684	Nov 03 05:07 PM
Albers Jeffrey W.	Director	Nov 02 '23	Sale	60.37	4,634	279,749	176,050	Nov 03 05:07 PM
Albers Jeffrey W.	Director	Nov 01 '23	Option Exercise	36.05	3,881	139,910	179,931	Nov 03 05:07 PM
Albers Jeffrey W.	Director	Nov 01 '23	Sale	60.02	3,881	232,938	176,050	Nov 03 05:07 PM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Oct 26 '23	Sale	56.40	600	33,840	25,095	Oct 30 02:01 PM
Namouni Fouad	PRESIDENT, R & D	Oct 04 '23	Sale	48.06	3,769	181,138	62,080	Oct 05 10:47 AM
Albers Jeffrey W.	Director	Sep 28 '23	Option Exercise	1.87	6,898	12,899	182,948	Sep 29 02:36 PM
Albers Jeffrey W.	Director	Sep 28 '23	Sale	50.17	6,898	346,073	176,050	Sep 29 02:36 PM
Albers Jeffrey W.	Director	Sep 27 '23	Option Exercise	1.87	18,102	33,851	194,152	Sep 29 02:36 PM
Albers Jeffrey W.	Director	Sep 27 '23	Sale	49.61	18,102	897,957	176,050	Sep 29 02:36 PM
Albers Jeffrey W.	Director	Aug 25 '23	Option Exercise	1.87	10,000	18,700	186,050	Aug 28 06:23 PM
Albers Jeffrey W.	Director	Aug 25 '23	Sale	50.16	10,000	501,600	176,050	Aug 28 06:23 PM
Albers Jeffrey W.	Director	Aug 24 '23	Option Exercise	1.87	15,000	28,050	191,050	Aug 28 06:23 PM
Albers Jeffrey W.	Director	Aug 24 '23	Sale	49.57	15,000	743,550	176,050	Aug 28 06:23 PM
Carter Percy H.	CHIEF SCIENTIFIC OFFICER	Jun 05 '23	Sale	52.06	2,307	120,102	38,117	Jun 07 07:52 PM
Hewes L. Becker	CHIEF MEDICAL OFFICER	Jun 05 '23	Sale	52.05	1,404	73,078	36,878	Jun 07 07:48 PM

Open in Screener

KYMR

Kymera Therapeutics Inc

Apr 30 • 04:00PM ET

33.62

Dollar change -1.04
Percentage change -3.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

KYMR Kymera Therapeutics Inc daily Stock Chart

Held by: VTI VB IWM VBK VXF IBB IWO SCHA VTWO LABU

Index	RUT	P/E	-	EPS (ttm)	-2.52	Insider Own	11.38%	Shs Outstand	55.59M	Perf Week	-5.85%
Market Cap	2.06B	Forward P/E	-	EPS next Y	-3.38	Insider Trans	-6.58%	Shs Float	54.38M	Perf Month	-14.71%
Income	-146.96M	PEG	-	EPS next Q	-0.72	Inst Own	89.82%	Short Float	17.84%	Perf Quarter	2.50%
Sales	78.59M	P/S	26.25	EPS this Y	-19.97%	Inst Trans	3.67%	Short Ratio	15.26	Perf Half Y	206.47%
Book/sh	7.11	P/B	4.73	EPS next Y	-11.65%	ROA	-24.93%	Short Interest	9.70M	Perf Year	6.59%
Cash/sh	6.11	P/C	5.50	EPS next 5Y	1.90%	ROE	-33.21%	52W Range	9.60 - 45.31	Perf YTD	32.05%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-39.18%	ROI	-31.05%	52W High	-25.80%	Beta	2.30
Dividend TTM	-	Quick Ratio	4.73	Sales past 5Y	241.22%	Gross Margin	95.46%	52W Low	250.21%	ATR (14)	1.77
Dividend Ex-Date	-	Current Ratio	4.73	EPS Y/Y TTM	12.49%	Oper. Margin	-210.62%	RSI (14)	40.76	Volatility	3.75% 4.70%
Employees	187	Debt/Eq	0.21	Sales Y/Y TTM	67.84%	Profit Margin	-186.99%	Recom	1.71	Target Price	51.07
Option/Short	Yes / Yes	LT Debt/Eq	0.20	EPS Q/Q	59.24%	Payout	-	Rel Volume	0.76	Prev Close	34.66
Sales Surprise	14.17%	EPS Surprise	38.04%	Sales Q/Q	196.70%	Earnings	May 02 BMO	Avg Volume	635.60K	Price	33.62
SMA20	-4.94%	SMA50	-13.35%	SMA200	30.79%	Trades		Volume	481,498	Change	-3.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Initiated	Oppenheimer	Outperform	$53
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Jan-04-24	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral	$45 → $30
Dec-19-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$26
Jun-30-23	Initiated	Truist	Buy	$50
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform
Dec-06-22	Downgrade	Credit Suisse	Outperform → Neutral	$47 → $32
Nov-08-22	Initiated	Raymond James	Mkt Perform
Aug-15-22	Initiated	Jefferies	Buy	$40
Aug-03-22	Initiated	Goldman	Buy	$40
Jul-20-22	Initiated	SVB Leerink	Mkt Perform	$26
Apr-28-22	Initiated	Credit Suisse	Outperform	$63
Mar-10-22	Initiated	JP Morgan	Neutral	$44
Feb-10-22	Initiated	Wells Fargo	Overweight	$62
Sep-30-21	Initiated	Stifel	Buy	$80
Sep-30-21	Initiated	B. Riley Securities	Neutral	$67
Sep-10-21	Downgrade	BofA Securities	Buy → Neutral	$65 → $80
May-21-21	Initiated	UBS	Buy	$80
Apr-14-21	Initiated	Berenberg	Buy

Show Previous Ratings

Apr-25-24 10:02AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) -5.28%
09:20AM	20 Counties with the Highest Cancer Rates in the US (Insider Monkey)
07:00AM	Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 (GlobeNewswire)
Apr-08-24 07:00AM	Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting (GlobeNewswire)
Mar-08-24 10:00AM	Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting (GlobeNewswire)
11:27PM	Loading…
Mar-04-24 11:27PM	Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR) (GuruFocus.com)
Feb-28-24 07:00AM	Kymera Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-23-24 11:59AM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 11:24PM	Q4 2023 Kymera Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:35AM	Kymera Therapeutics Inc (KYMR) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
07:00AM	Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-21-24 11:52PM	Director Jeffrey Albers Sells 5,000 Shares of Kymera Therapeutics Inc (KYMR) (GuruFocus.com)
Feb-15-24 10:00AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:00AM	Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22 (GlobeNewswire)
Feb-10-24 02:56AM	Chief Medical Officer Jared Gollob Sells 46,137 Shares of Kymera Therapeutics Inc (GuruFocus.com)
07:00AM	Loading…
Jan-31-24 07:00AM	Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference (GlobeNewswire)
Jan-24-24 12:20AM	Director Jeffrey Albers Sells 10,000 Shares of Kymera Therapeutics Inc (GuruFocus.com)
Jan-17-24 08:00AM	INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors (GlobeNewswire)
Jan-09-24 09:17AM	Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs (GlobeNewswire) +7.80%
09:15AM	Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-05-24 04:03PM	Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering (Investor's Business Daily)
06:00AM	Kymera Therapeutics Announces Pricing of $275 Million Public Offering (GlobeNewswire)
Jan-04-24 04:01PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire) +18.86%
07:00AM	R&D Day Highlights Kymera's Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases (GlobeNewswire)
Jan-02-24 07:00AM	Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 (GlobeNewswire)
Dec-22-23 10:45AM	Kymera Therapeutics Has Doubled in 2 Months, But Is the Upside Sustainable? (TheStreet.com)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
Dec-13-23 07:00AM	Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4 (GlobeNewswire) +7.33%
Dec-10-23 09:00PM	Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-08-23 11:13AM	Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474 (Zacks)
07:00AM	Loading…
Dec-07-23 07:00AM	Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi (GlobeNewswire) +7.20%
Nov-13-23 11:00AM	Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine (GlobeNewswire)
Nov-07-23 09:05AM	BIOTECHNOLOGY VALUE FUND L P Adds to Its Stake in Kymera Therapeutics Inc (GuruFocus.com) +13.61%
Nov-05-23 02:38PM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 09:00AM	Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting (GlobeNewswire)
08:43AM	Kymera Therapeutics Inc (KYMR) Announces Q3 2023 Financial Results (GuruFocus.com)
07:00AM	Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-01-23 07:00AM	Kymera Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-27-23 07:00AM	Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi (GlobeNewswire)
Oct-26-23 10:02AM	Will Kymera Therapeutics, Inc. (KYMR) Report Negative Q3 Earnings? What You Should Know (Zacks)
07:00AM	Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2 (GlobeNewswire)
Oct-19-23 09:35AM	Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-18-23 09:35AM	Kymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-16-23 07:00AM	Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma (GlobeNewswire)
Oct-04-23 06:23AM	Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks)
Oct-03-23 04:48PM	Why Shares of Kymera Therapeutics Jumped on Tuesday (Motley Fool) +14.30%
Sep-18-23 07:00AM	Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma (GlobeNewswire)
Aug-28-23 07:00AM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-03-23 08:25AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +11.07%
07:00AM	Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Jul-27-23 07:00AM	Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3 (GlobeNewswire)
Jul-09-23 09:09AM	Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth (Simply Wall St.)
Jun-22-23 08:30AM	Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia (GlobeNewswire)
Jun-14-23 02:30AM	Kymera Therapeutics STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials (GlobeNewswire)
Jun-09-23 06:00PM	Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 (GlobeNewswire)
03:00AM	Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress (GlobeNewswire)
Jun-01-23 07:00AM	Kymera Therapeutics to Participate in Upcoming June Investor Conference (GlobeNewswire)
May-29-23 12:24PM	Investors in Kymera Therapeutics (NASDAQ:KYMR) have seen notable returns of 95% over the past year (Simply Wall St.)
May-22-23 07:00AM	Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer (GlobeNewswire)
May-19-23 07:00AM	Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253 (GlobeNewswire)
May-18-23 07:00AM	Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium (GlobeNewswire)
May-14-23 02:57PM	7 Growth Stocks That Could Double Your Money in 2023 (InvestorPlace)
May-09-23 03:15PM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-04-23 08:25AM	Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -15.08%
07:00AM	Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-19-23 11:11AM	Some Shareholders Feeling Restless Over Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) P/S Ratio (Simply Wall St.)
Apr-11-23 07:00AM	Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4 (GlobeNewswire)
Apr-09-23 01:19PM	7 Biotech Stocks to Buy for 100% Returns (InvestorPlace)
Mar-09-23 03:00PM	12 Small-Cap Stocks With Insider Buying (Insider Monkey)
Mar-03-23 11:40AM	15 Most Shorted Stocks Right Now on Wall Street (Insider Monkey)
Mar-01-23 07:00AM	Kymera Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-24-23 02:53AM	Q4 2022 Kymera Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -5.13%
Feb-23-23 08:25AM	Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +5.17%
07:00AM	Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-01-23 07:00AM	Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23 (GlobeNewswire)
Jan-31-23 08:00AM	X-Chem and Kymera Expand Existing Partnership (Business Wire)
Jan-30-23 07:26AM	We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely (Simply Wall St.)
Jan-23-23 04:14AM	Revance Therapeutics, Inc. (RVNC) Soars 8.6%: Is Further Upside Left in the Stock? (Zacks)
Jan-17-23 06:27AM	Daily Vickers Top Buyers & Sellers for 01/17/2023 (Argus Research)
Jan-10-23 07:00AM	Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company (GlobeNewswire) +9.14%
Jan-09-23 12:00PM	All You Need to Know About Kymera Therapeutics, Inc. (KYMR) Rating Upgrade to Buy (Zacks)
Jan-04-23 07:00AM	Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Jan-03-23 07:00AM	Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 (GlobeNewswire)
Dec-21-22 04:57PM	7 Perfect Presents to Gift Your 2023 Stock Portfolio (InvestorPlace)
Dec-20-22 10:33AM	Shareholders in Kymera Therapeutics (NASDAQ:KYMR) are in the red if they invested a year ago (Simply Wall St.)
Dec-15-22 10:27AM	Kymera (KYMR) Up on Positive Data From Phase I Study on KT-474 (Zacks) -5.81%
Dec-14-22 04:09PM	Small Biotech Kymera Just Snagged Sanofi's Interest Here's Why (Investor's Business Daily) +14.58%
01:44PM	These Biotech Stocks Are the Nasdaq's Big Wednesday Winners (Motley Fool)
10:00AM	Kymera Therapeutics Stock Jumps After Positive Data From Atopic Dermatitis Trial (Benzinga)
07:57AM	Kymera's stock rallies as it plans to move treatment into Phase 2 studies next year (MarketWatch)
07:00AM	Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofis Decision to Advance KT-474 into Phase 2 Clinical Trials (GlobeNewswire)
Dec-12-22 10:00AM	Preclinical Data from Kymera Therapeutics Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting (GlobeNewswire) +8.11%
Dec-11-22 10:00AM	Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-01-22 07:00AM	Kymera Therapeutics Provides Webcast Information for December 14 Investor Event (GlobeNewswire)
Nov-09-22 06:16AM	Kymera Therapeutics Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) -8.24%
Nov-05-22 08:33AM	These Analysts Think Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Sales Are Under Threat (Simply Wall St.)
Nov-03-22 08:35AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +7.55%
07:05AM	Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update (GlobeNewswire)
07:00AM	Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors (GlobeNewswire)

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Booth Bruce	Director	Mar 15 '24	Sale	40.46	71,764	2,903,336	806,697	Mar 15 07:23 PM
Booth Bruce	Director	Mar 14 '24	Sale	39.98	55,779	2,229,927	819,151	Mar 15 07:23 PM
Booth Bruce	Director	Mar 13 '24	Sale	42.23	139,255	5,880,415	828,830	Mar 13 07:52 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 13 '24	Sale	42.23	115,090	4,859,993	4,676,075	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 13 '24	Sale	42.23	24,165	1,020,422	828,830	Mar 13 07:53 PM
Booth Bruce	Director	Mar 12 '24	Sale	41.98	162,918	6,838,813	852,995	Mar 13 07:52 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 12 '24	Sale	41.98	134,647	5,652,072	4,791,165	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 12 '24	Sale	41.98	28,271	1,186,741	852,995	Mar 13 07:53 PM
Booth Bruce	Director	Mar 11 '24	Sale	42.85	51,184	2,193,148	881,266	Mar 13 07:52 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 11 '24	Sale	42.85	42,302	1,812,586	4,925,812	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 11 '24	Sale	42.85	8,882	380,562	881,266	Mar 13 07:53 PM
Jacobs Bruce N.	Chief Financial Officer	Mar 04 '24	Sale	41.86	3,934	164,664	142,351	Mar 04 06:12 PM
Gollob Jared	Chief Medical Officer	Mar 04 '24	Sale	41.86	3,344	139,967	95,740	Mar 04 06:21 PM
Albers Jeffrey W.	Director	Feb 21 '24	Option Exercise	10.34	4,385	45,341	4,385	Feb 21 06:46 PM
Albers Jeffrey W.	Director	Feb 21 '24	Sale	39.05	4,385	171,227	0	Feb 21 06:46 PM
Albers Jeffrey W.	Director	Feb 20 '24	Option Exercise	10.34	615	6,359	615	Feb 21 06:46 PM
Albers Jeffrey W.	Director	Feb 20 '24	Sale	39.07	615	24,031	0	Feb 21 06:46 PM
Gollob Jared	Chief Medical Officer	Feb 09 '24	Option Exercise	2.08	46,137	95,965	120,846	Feb 09 07:47 PM
Gollob Jared	Chief Medical Officer	Feb 09 '24	Sale	35.50	46,137	1,638,071	74,709	Feb 09 07:47 PM
Albers Jeffrey W.	Director	Jan 23 '24	Option Exercise	10.34	10,000	103,400	10,000	Jan 23 07:37 PM
Albers Jeffrey W.	Director	Jan 23 '24	Sale	30.05	10,000	300,470	0	Jan 23 07:37 PM
Chiniara Ellen	Chief Legal Officer	Jan 04 '24	Sale	22.58	3,295	74,416	34,205	Jan 05 05:15 PM
Mainolfi Nello	Chief Executive Officer	Jan 02 '24	Option Exercise	2.08	9,000	18,720	615,570	Jan 02 05:43 PM
Mainolfi Nello	Chief Executive Officer	Nov 03 '23	Option Exercise	2.08	20,000	41,600	606,570	Nov 06 06:00 PM
BVF PARTNERS L P/IL	Director	Nov 03 '23	Buy	14.07	197,699	2,781,407	2,656,191	Nov 06 06:07 PM
BVF PARTNERS L P/IL	Director	Nov 02 '23	Buy	11.64	216,406	2,519,918	2,552,306	Nov 06 06:07 PM
Mainolfi Nello	Chief Executive Officer	Aug 08 '23	Option Exercise	2.08	12,000	24,960	586,570	Aug 08 04:30 PM
Jacobs Bruce N.	Chief Financial Officer	Jun 02 '23	Option Exercise	2.08	10,000	20,800	115,035	Jun 02 02:17 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

BPMC

Blueprint Medicines Corp

KYMR

Kymera Therapeutics Inc

Upgrade your FINVIZ experience